SynDermix is a Swiss developer of innovative health technologies that focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
SDX-31 is an electronic medical device platform based on Precisely Modulated Acoustic Energy™ (PMAE) therapy; a proprietary type of treatment during which digitally controlled acoustic frequencies are generated
SDX-21 is a platform based on an endogenous Nitric Oxide (NO) donor in an easy-to-use formulation, which can be leveraged for the development of drug products or medical devices, depending on the selected indication
SDX-13 is a drug platform based on a novel recombinant plant lectin with positive Phase IIa results in epithelial healing and a favourable safety profile
Together, our executive team, specialist partners and company values combine to sustain ground-breaking health science and process excellence.
Our newsroom provides information on our latest developments and the events we will be attending.
SynDermix is a privately funded company. Investors and other account holders, please click here to log in.
